Latest Conference Articles

Oleclumab plus durvalumab and chemotherapy did not increase clinical benefit rate for patients with advanced triple-negative breast cancer, according to results from the phase 2 SYNERGY trial.

Treatment with sactiuzumab govitecan improved overall survival, objective response rate, duration of response, and overall quality of life vs physician’s choice in the phase 3 TROPiCS-02 study.

The phase 2 NEOpredict trial of nivolumab with or without relatilmab met its primary end point of feasibility of treatment in patients with resectable non–small cell lung cancer.

Rhenium-186 nanoliposome at doses exceeding 100 Gy showed promising results in patients with recurrent glioma, according to phase 1 findings from the ReSPECT-GBM trial presented at ESMO 2022.

Updated findings of the MONARCH 3 trial of abemaciclib added to a nonsteroidal aromatase inhibitor presented at ESMO 2022 revealed prolonged overall survival in hormone receptor-positive, HER2-negative breast cancer.

Findings from the phase 3 SOLO1/GOG-3004 trial presented at ESMO 2022 support maintenance therapy with olaparib in women with newly diagnosed advanced ovarian cancer.

Findings from the phase 3 ARIEL4 trial of rucaparib vs chemotherapy in relapsed ovarian cancer with deleterious BRCA1/2 mutations raised questions about optimal sequencing of PARP inhibitors at ESMO 2022.

Adding olaparib to bevacizumab maintenance therapy following treatment with first-line standard-of-care treatment revealed am improvement in overall survival in advanced ovarian cancer and homologous recombination deficiency.

The phase 2 CARTITUDE study showed encouraging response in the heavily-pretreated multiple myeloma population. Now, the phase 3 CARTITUDE-4 trial is underway.

An association between biallelic deletion of TNFRSF17 and resistance to therapies like chimeric antigen receptor T cells and T-cell engagers has been identified in myeloma.

The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.

Results of a phase 1 trial of the bispecific antibody ABBV-383 showed a high overall response rate and manageable adverse event profile in patients with relapsed/refractory multiple myeloma.

Results shown from studies of bispecific antibodies, immunomodulatory drugs , and antibody-drug conjugates signal a bright future for relapsed or refractory myeloma treatment.

No significant survival differences were shown between 2 high-dose regimens for newly diagnosed multiple myeloma. However, certain prognostic factors may improve or decrease survival.

Patients with relapsed or refractory multiple myeloma who relapsed after treatment with B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy.

Final overall survival in the ICARIA-MM study favored the combination of Isatuximab-irfc plus pomalidomide and low-dose dexamethasone.

Updated analysis results of from the IKEMA showed improvement in the depth of response to isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma.

In LINKER-MM1 study, responses to REGN5458 occurred early, were durable, and deepened over time.

Post-hoc analysis findings from phase 2 DREAMM-2 trial show no relationship between ocular conditions found at baseline in patients with relapsed or refractory multiple myeloma and ocular toxicity from belantamab mafodotin.

Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.

Data presented at the 19th International Myeloma Society Annual Meeting show that carfilzomib plus lenalidomide and dexamethasone after transplant prolongs progression-free survival compared with lenalidomide alone in patients with myeloma.

A study of real-world outcomes of patient with relapsed or refractory multiple myeloma treated with isatuximab in now enrolling.

Patients with treatment-naive myeloma treated with humanized IgGx CD38-targeted monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone for at least 18 months had a overall survival benefit in the phase 3 MAIA study.

Updated analysis of the IKEMA trial showed the combination of isatuximab, carfilzomib, and dexamethasone to elicit superior progression-free survival vs carfilzomib and dexamethasone alone in patients with multiple myeloma.

Findings from the phase 3 DETERMINATION trial show lenalidomide plus bortezomib, dexamethasone, and autologous stem cell transplantation to improve progression-free survival in patients with multiple myeloma.

Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation allowed 70% of patients with high-risk, newly diagnosed multiple myeloma to complete a second autologous stem cell transplant.

Meaningful progression-free survival and safety elicited with isatuximab plus pomalidomide and dexamethasone treatment in real-world multiple myeloma population.

Kashyap Patel, MD, discusses the current disparities in the myeloma space and the ways in which oncologists are handling them.

In real-world patients with relapsed or refractory multiple myeloma, isatuximab-based regimens were found to be tolerable.

Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.